Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Regeneron says Sanofi to have sole Praluent responsibility outside U.S. » 17:09
04/06/20
04/06
17:09
04/06/20
17:09
SNY

Sanofi

$46.14 /

+1.25 (+2.78%)

, REGN

Regeneron

$504.27 /

+11.135 (+2.26%)

Regeneron (REGN)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
Fly Intel: Wall Street's top stories for Monday » 16:57
04/06/20
04/06
16:57
04/06/20
16:57
DAL

Delta Air Lines

$22.15 /

-0.33 (-1.47%)

, UAL

United Airlines

$23.99 /

+1.1 (+4.81%)

, JBLU

JetBlue

$7.72 /

+0.25 (+3.35%)

, LUV

Southwest

$30.70 /

+0.17 (+0.56%)

, ALK

Alaska Air

$26.64 /

+1.99 (+8.07%)

, BA

Boeing

$148.58 /

+23.99 (+19.26%)

, EADSY

Airbus

$0.00 /

+ (+0.00%)

, ZM

Zoom Video

$122.90 /

-5.18 (-4.04%)

, MSFT

Microsoft

$165.27 /

+11.35 (+7.37%)

, FB

Facebook

$165.42 /

+11.23 (+7.28%)

, TSN

Tyson Foods

$56.48 /

+2.73 (+5.08%)

, IMMU

Immunomedics

$18.77 /

+9.38 (+99.89%)

, W

Wayfair

$71.53 /

+20.86 (+41.17%)

, CODX

Co-Diagnostics

$10.29 /

+2.095 (+25.56%)

, CCL

Carnival

$10.19 /

+1.7 (+20.02%)

, LK

Luckin Coffee

$4.38 /

-0.98 (-18.28%)

, SMPL

Simply Good Foods

$17.12 /

-1.58 (-8.45%)

Stocks jumped to start…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
Fly Intel: Wall Street's top stories at midday » 13:21
04/06/20
04/06
13:21
04/06/20
13:21
DAL

Delta Air Lines

$22.36 /

-0.12 (-0.53%)

, UAL

United Airlines

$24.16 /

+1.265 (+5.53%)

, JBLU

JetBlue

$7.85 /

+0.38 (+5.09%)

, BRK.A

Berkshire Hathaway

$275,286.00 /

+6786 (+2.53%)

, BRK.B

Berkshire Hathaway

$183.00 /

+4.76 (+2.67%)

, LUV

Southwest

$30.85 /

+0.32 (+1.05%)

, BA

Boeing

$138.25 /

+13.66 (+10.96%)

, ZM

Zoom Video

$120.02 /

-8.06 (-6.29%)

, MSFT

Microsoft

$161.58 /

+7.66 (+4.98%)

, IMMU

Immunomedics

$18.35 /

+8.96 (+95.42%)

, W

Wayfair

$70.75 /

+20.08 (+39.63%)

, CODX

Co-Diagnostics

$10.35 /

+2.155 (+26.30%)

, CCL

Carnival

$10.36 /

+1.87 (+22.03%)

, CUK

Carnival plc

$9.34 /

+1.4 (+17.63%)

, LK

Luckin Coffee

$4.55 /

-0.81 (-15.11%)

, SMPL

Simply Good Foods

$17.68 /

-1.02 (-5.45%)

The S&P, Dow and…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Cantor pharma/biotech analysts to hold analyst/industry conference call » 10:25
04/06/20
04/06
10:25
04/06/20
10:25
PFE

Pfizer

$34.48 /

+0.85 (+2.53%)

, LLY

Eli Lilly

$141.85 /

+2.34 (+1.68%)

, MRK

Merck

$79.52 /

+3.26 (+4.27%)

, MRTX

Mirati Therapeutics

$81.81 /

+8.3 (+11.29%)

, AMGN

Amgen

$209.13 /

+3.73 (+1.82%)

, JNJ

Johnson & Johnson

$136.45 /

+2.32 (+1.73%)

, PHGE

BiomX

$6.17 /

+ (+0.00%)

Cantor Fitzgerald…

Cantor Fitzgerald Pharmaceuticals Analyst Chen & Kim, Biotech Analysts Young, Kumar & Kluska, along with Dr. Robert Fine from New York-Presbyterian/Columbia University Medical Center review current treatment paradigm for advanced and metastatic colorectal cancer (CRC) and discuss new treatments for CRC on an Analyst/Industry conference call to be held on April 6 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Unusually active option classes on open April 6th » 09:40
04/06/20
04/06
09:40
04/06/20
09:40
MNK

Mallinckrodt

$1.70 /

+ (+0.00%)

, PENN

Penn National

$9.75 /

+ (+0.00%)

, LUV

Southwest

$30.53 /

+ (+0.00%)

, DAL

Delta Air Lines

$22.48 /

+ (+0.00%)

, USO

United States Oil Fund

$5.91 /

+0.005 (+0.08%)

, ACB

Aurora Cannabis

$0.80 /

+ (+0.00%)

, M

Macy's

$4.81 /

+ (+0.00%)

, MSFT

Microsoft

$153.92 /

+ (+0.00%)

, TEVA

Teva

$8.40 /

+ (+0.00%)

, GILD

Gilead

$78.22 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: Mallinckrodt (MNK), Penn National (PENN), Southwest (LUV), Delta Air Lines (DAL), United States Oil Fund (USO), Aurora Cannabis (ACB), Macy's (M), Microsoft (MSFT), Teva (TEVA), and Gilead (GILD).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
Fly Intel: Pre-market Movers » 09:11
04/06/20
04/06
09:11
04/06/20
09:11
CODX

Co-Diagnostics

$8.20 /

-0.275 (-3.25%)

, AXSM

Axsome Therapeutics

$54.98 /

-0.68 (-1.22%)

, SEAS

SeaWorld

$9.03 /

-0.655 (-6.77%)

, TEN

Tenneco

$2.31 /

-0.64 (-21.69%)

, XBIT

XBiotech

$11.49 /

+0.54 (+4.93%)

, TSLA

Tesla

$479.71 /

+25.715 (+5.66%)

, SMPL

Simply Good Foods

$18.70 /

+0.57 (+3.14%)

, DGLY

Digital Ally

$0.73 /

+0.0088 (+1.22%)

, DAL

Delta Air Lines

$22.48 /

-0.19 (-0.84%)

, TDY

Teledyne

$290.00 /

-1.51 (-0.52%)

, MNLO

Menlo Therapeutics

$2.61 /

-0.03 (-1.14%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
GlaxoSmithKline, Vir Biotechnology collaborate for coronavirus solutions » 08:54
04/06/20
04/06
08:54
04/06/20
08:54
GSK

GlaxoSmithKline

$37.11 /

-0.61 (-1.62%)

, VIR

Vir Biotechnology

$28.86 /

-0.3 (-1.03%)

GlaxoSmithKline plc (GSK)…

GlaxoSmithKline plc (GSK) and Vir Biotechnology, Inc. (VIR) announced they have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration will use Vir's proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventative options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK's expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines. Due to the urgent patient need for COVID-19 solutions, the initial focus of the collaboration will be to accelerate the development of specific antibody candidates identified by the Vir platform, VIR-7831 and VIR-7832, that have demonstrated high affinity for the SARS-CoV-2 spike protein and are highly potent in neutralising SARS-CoV-2 in live virus-cellular assays. Subject to regulatory review, the companies plan to proceed directly into a phase 2 clinical trial within the next three to five months. The collaboration will also utilise Vir's CRISPR screening and machine learning approach to identify cellular targets whose inhibition can prevent viral infection. Vir has identified multiple potential targets against flu and other respiratory pathogens, as well as hepatitis B virus, and will now focus on SARS-CoV-2. Additionally, the companies have also agreed to conduct research into SARS-CoV-2 and other coronavirus vaccines by coupling GSK's vaccines technologies and expertise with Vir's ability to identify neutralising epitopes that are present across entire viral families. These efforts will be additive to other initiatives GSK is advancing to develop a potential vaccine for COVID-19. In addition, to gain access to Vir's technology, GSK will make an equity investment in Vir of $250M, priced at $37.73, a 10% premium to the closing share price on Friday, March 27, 2020. The equity investment and collaboration agreement will complete at the same time and are conditional upon customary conditions including regulatory review by the appropriate regulatory agencies under the Hart-Scott-Rodino Act.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Inovio: FDA accepts IND application for INO-4800 » 08:41
04/06/20
04/06
08:41
04/06/20
08:41
INO

Inovio

$7.73 /

+0.23 (+3.07%)

Inovio announced that the…

Inovio announced that the U.S. FDA has accepted the company's Investigational New Drug application for INO-4800, its DNA vaccine candidate designed to prevent COVID-19 infection, paving the way for Phase 1 clinical testing of INO-4800 in healthy volunteers beginning this week. The first dosing is planned for April 6.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Co-Diagnostics COVID-19 test obtains EUA from FDA » 06:34
04/06/20
04/06
06:34
04/06/20
06:34
CODX

Co-Diagnostics

$8.20 /

-0.275 (-3.25%)

Co-Diagnostics announced…

Co-Diagnostics announced that its Logix Smart coronavirus COVID-19 Test has obtained emergency use authorization, or EUA, by the FDA to be used for the diagnosis of SARS-CoV-2. The company's test can be used by clinical laboratories certified under Clinical Laboratory Improvement Amendments, or CLIA, to detect the presence of the virus that causes COVID-19, and is available for purchase from the company's Utah-based facility. Co-Diagnostics began offering its COVID-19 test to some U.S. CLIA labs in March as a result of the FDA's policy for diagnostic tests for COVID-19 during the current public health emergency. Previously, the company had initiated sales of its CE-IVD test to the European community, and to other global markets that accept a CE marking as valid regulatory approval following routine local product registration. The Co-Diagnostics Logix Smart coronavirus COVID-19 Test uses the company's patented CoPrimer technology to target the RdRp gene of the SARS-CoV-2 virus. The advanced nature of CoPrimers has allowed Co-Diagnostics to design a highly-specific, single-well PCR test, allowing higher throughput over tests that require multiple wells.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Gilead, Second Genome collaborate on IBD treatments » 06:17
04/06/20
04/06
06:17
04/06/20
06:17
GILD

Gilead

$78.22 /

+1.255 (+1.63%)

Gilead Sciences and…

Gilead Sciences and Second Genome announced that the companies have entered into a four-year strategic collaboration to identify biomarkers associated with clinical response in up to five of Gilead's pipeline compounds in inflammation, fibrosis and other diseases, and to identify potential new targets and drug candidates for the treatment of inflammatory bowel disease. Under the terms of the agreement, Second Genome will utilize its proprietary Microbiome Analytics Platform to identify novel biomarkers associated with clinical response to Gilead's investigational medicines. This work will harness the latest insights in microbiome science to help inform patient stratification and optimize potential treatments for patients in the future. The platform, in combination with additional discovery and development tools, will also seek to identify new targets and drug candidates relevant to IBD. This will include the identification of up to five novel IBD targets or drug candidates over the next four years, with an option to extend the collaboration for an additional two years. Second Genome will receive $38M in an upfront payment, and up to approximately $300M in success-based preclinical, clinical, regulatory and commercial milestones for each of five target discovery programs as well as low double-digit royalties for any approved products. In addition, it will receive success-based milestones for each validated biomarker delivered under the agreement. Gilead will have the option to worldwide rights for up to five programs for all diseases as well as exclusive rights to all biomarkers developed under the collaboration.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.